Mounjaro with a BMI of 29: what the licensed criteria actually say

How the licensed threshold was set, and why 29 can qualify

The UK authorisation for Mounjaro is grounded in the SURMOUNT clinical programme. SURMOUNT-1, published in the New England Journal of Medicine, enrolled adults with a BMI of 30 or above, plus a separate cohort with BMI 27–29.9 and at least one weight-related comorbidity. That second cohort matters: it is the direct evidence base for the 27-plus arm of the licence. Participants in that range saw clinically meaningful weight reductions, which supported the MHRA's decision to licence tirzepatide down to BMI 27 provided a qualifying condition exists.

So the question for someone at BMI 29 is not whether the number clears a hurdle (it does) but whether a relevant health condition is present. Hypertension, dyslipidaemia, prediabetes, type 2 diabetes, obstructive sleep apnoea and osteoarthritis are among the conditions the SmPC and UK guidance recognise. If one or more of those applies to you, a prescriber can legitimately consider Mounjaro. If none does, the licence does not support its use at that BMI. That distinction is not a technicality; it reflects what the trial evidence was designed to show.

You can read more about how BMI interacts with eligibility across the licensed range on our full Mounjaro BMI guide, which covers the broader eligibility picture.

NHS criteria versus the licensed criteria at a BMI of 29

It is worth separating two different frameworks, because they often get conflated. The NICE technology appraisal TA1026 sets out a phased NHS rollout of tirzepatide starting at BMI 40 with multiple comorbidities and working downward over several years. A BMI of 29 is not within any current or near-future NHS cohort under that schedule. That is an NHS commissioning decision driven by resource allocation, not a statement about the medicine's licence.

Private prescribing, by contrast, follows the licensed criteria. A GPhC-registered prescriber in a private setting can prescribe Mounjaro to an adult with BMI 27–29.9 who has a qualifying condition, because that is what the authorisation permits. The two systems run in parallel, NHS access is phased and restricted; private access reflects the full licence, subject to clinical assessment.

This is why a BMI of 29 with, say, newly diagnosed hypertension may be eligible privately even though no NHS route exists. Our Mounjaro overview page sets out both routes in more detail.

What a prescriber looks at beyond the BMI figure

At BMI 29, the eligibility conversation shifts almost entirely to health context. A prescriber reviewing your case will look at which conditions are present and how well managed they are, your medication history, any contraindications (certain GI conditions, a personal or family history of medullary thyroid cancer, and a small number of others), and your broader goals and lifestyle. The BMI number is the starting point, not the conclusion.

Tirzepatide is not recommended during pregnancy, breastfeeding, or for anyone under 18. A prescriber will also check for medicines that may interact, including oral contraceptives, the SmPC advises adding a non-oral method of contraception for the first four weeks of tirzepatide use and for four weeks after each dose increase, because gastric slowing can reduce oral contraceptive absorption.

If you want to understand how people with a BMI one step lower approach eligibility, the BMI 28 page covers that specific scenario. The key point at any sub-30 BMI is that a qualifying condition is not a box-tick formality; it is the clinical reason the prescriber can justify the prescription.

Practical next steps if your BMI is around 29

If you have a qualifying condition and your BMI is 29, the most useful thing you can do is gather a factual picture of your health before a consultation: blood-pressure readings, any recent lipid or blood-glucose results, and a record of any relevant diagnoses. That lets a prescriber make an informed assessment quickly. If you are also curious whether you might qualify at a slightly lower weight, our guide to Mounjaro eligibility at BMI 27 explains how the criteria apply at the lower end of the licensed range, and our page on Mounjaro at BMI 25 addresses questions about eligibility below the licensed threshold. The NHS BMI calculator is a straightforward way to confirm your exact figure if you are unsure.

Bear in mind that treatment pricing for private prescriptions is a separate conversation from eligibility. If you are weighing up the cost side, our pricing page explains what a private Mounjaro prescription typically includes; it is worth reading before you decide whether private treatment suits you.

At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber. If you order before 12pm on a working day and are approved, your treatment is dispatched the same day and arrives the next working day via DPD, in plain packaging. Treatment, consultation, prescription and delivery are included in one price, with 7-day aftercare, no subscriptions and no hidden fees. If you are ready to find out whether your health picture meets the criteria, you can start your free consultation today.